Announcement
25.10.2011


On 27 September 2011, NeuroSearch announced a comprehensive restructuring of
the company's operations in order to optimise financial and managerial
resources to complete the development of Huntexil®. A controlled
discontinuation of other activities was announced to take place, including a
gradual wind down of research activities in both the NsDiscovery division in
Ballerup and in NeuroSearch Sweden AB in Gothenburg.

Consequently, as of today, Thomas Varming, EVP, NsDiscovery, and Nicholas
Waters, EVP, NeuroSearch Sweden AB, have resigned from the executive management
group.

Patrik Dahlen, CEO of NeuroSearch, commented:
“I wish to thank both Thomas and Nicholas for their valuable contributions to
NeuroSearch over the years and wish them the best of success in their future
endeavours.”

Patrik Dahlen
CEO


Contact persons
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097


About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil®, a unique drug in Phase III for the
treatment of the motor symptoms of Huntington's disease.

Fonds.24-11 - Management - uk.pdf